<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61358">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307149</url>
  </required_header>
  <id_info>
    <org_study_id>VLA013</org_study_id>
    <secondary_id>PHS IRB: 14-241</secondary_id>
    <nct_id>NCT02307149</nct_id>
  </id_info>
  <brief_title>Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma</brief_title>
  <official_title>Phase Ib Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viralytics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Viralytics</source>
  <brief_summary>
    <textblock>
      The study will use the established dose of CAVATAK with ipilimumab in patients with advanced
      melanoma for whom ipilimumab would be considered standard of care. Treatment with CAVATAK
      will be on days 1, 3, 5 and 8 and then both agents will be co-administered on days 22, 43,
      64 and 85. Patients with clinical benefit can continue CAVATAK every 3 weeks for up to one
      year,
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/ tolerance of multiple intratumoral injections of CAVATAK when given in conjunction with ipilimumab as assessed by incidence of dose-limiting toxicities (DLT).</measure>
    <time_frame>Up to 106 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the objective response rate to CAVATAK and ipilimumab in patients with metastatic melanoma using irRC-WHO criteria</measure>
    <time_frame>Up to 106 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>CAVATAK and ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAVATAK</intervention_name>
    <description>CAVATAK is a purified preparation of CVA21</description>
    <arm_group_label>CAVATAK and ipilimumab</arm_group_label>
    <other_name>Coxsackievirus A21, CVA21</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma</description>
    <arm_group_label>CAVATAK and ipilimumab</arm_group_label>
    <other_name>Yervoy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic or unresectable stage IIIc or IV melanoma for whom treatment
             with ipilimumab is indicated

          -  At least one tumor must qualify to be a target lesion for irRC-WHO

          -  ECOG of 0-1

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             performed within 72 hour prior to the start of treatment

          -  No active bleeding

          -  Life expectancy &gt; 12 weeks

        Exclusion Criteria:

          -  Prior ipilimumab treatment for metastatic melanoma (prior ipilimumab as adjuvant
             permitted if no ≥ grade 3 toxicity)

          -  Tumors to be injected lying in mucosal regions or close to airway, major blood vessel
             or spinal cord that could cause occlusion or compression due to tumor swelling or
             erosion

          -  Active autoimmune disease (excluding autoimmune thyroiditis or vitiligo)

          -  Patients with history of colitis

          -  Untreated brain metastases.

          -  Other active metastatic cancer requiring treatment

          -  Active infection requiring antibiotics

          -  Pregnant or lactating women

          -  Need for chronic steroids

          -  Within 28 days of enrollment: WBC &lt; 3.1 x 10⁹ /L; Hgb &lt; 9.0 g/dL; AST or ALT &gt; 1.5
             upper limit of normal (ULN); total bilirubin &gt; 1.9 g/dL; prior HIV; prior Hepatitis
             B; prior Hepatitis C; INR &gt; 1.5 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Curti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brendan Curti, MD</last_name>
    <phone>5032159948</phone>
    <email>brendan.curti@providence.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Fountain</last_name>
    <phone>5032152691</phone>
    <email>christopher.fountain@providence.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Daniels, MD, PhD</last_name>
      <phone>858-534-3801</phone>
      <email>gdaniels@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mario Orozco, CCRC</last_name>
      <phone>858 822 0201</phone>
      <email>mrorozco@ucsd.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Faries, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, SC</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Richards, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>James Puthenveetil</last_name>
      <phone>847 410 0659</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan D Curti, MD</last_name>
      <phone>503-215-5696</phone>
      <email>brendan.curti@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Christopher Fountain, RN</last_name>
      <phone>503 215 2691</phone>
      <email>Christopher.Fountain@providence.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Andtbacka, MD</last_name>
      <email>Robert.Andtbacka@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Willis</last_name>
      <email>tamara.willis@hci.utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 8, 2016</lastchanged_date>
  <firstreceived_date>November 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Coxsackievirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
